TARS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 114199 min ago

@ $29.83

Išleistas: 13 vas. 2024 @ 18:42

Grąža: 16.09%

Ankstesnis signalas: vas. 9 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: -3.38 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions...

Stats
Šios dienos apimtis	439 520
Vidutinė apimtis	701 663
Rinkos kapitalizacija	1.30B
EPS	$0 ( 2024-02-27 )
Kita pelno data	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.50
ATR14	$0.0760 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Mottiwala Aziz	Buy	12 938	Common Stock
2024-03-18	Mottiwala Aziz	Sell	4 766	Common Stock
2024-03-15	Mottiwala Aziz	Sell	8 148	Restricted Stock Units
2024-03-15	Mottiwala Aziz	Sell	4 790	Restricted Stock Units
2024-03-15	Wahl Bryan	Buy	12 038	Common Stock

INSIDER POWER
31.22
Last 100 transactions
Buy: 1 038 524 \| Sell: 656 594

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: -0.39 (neutral)

Signal:(64.229) Neutral

Tarsus Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SLDP	0.904
HOOK	0.897
USEG	0.893
RDHL	0.884
VIRX	0.875
SVFD	0.874
ONDS	0.869
XFOR	0.867
MARPS	0.864
PLXP	0.858

10 Labiausiai neigiamai susiję koreliacijos
ITMR	-0.864
AVEO	-0.862
EWEB	-0.854
HZNP	-0.851
OPNT	-0.844
MICT	-0.841
DVCR	-0.84
BNIXU	-0.834
OCCIP	-0.833
ACIW	-0.832

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Tarsus Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

0.25
( neutral )

-0.21
( neutral )

-0.56
( weak negative )

-0.18
( neutral )

-0.50
( neutral )

0.30
( neutral )

Tarsus Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	$17.45M
Bruto pelnas:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2023
Pajamos:	$17.45M
Bruto pelnas:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2022
Pajamos:	$25.82M
Bruto pelnas:	$24.86M (96.30 %)
EPS:	$-2.52

FY	2021
Pajamos:	$57.03M
Bruto pelnas:	$57.03M (100.00 %)
EPS:	$-0.00200

Financial Reports:

No articles found.

Tarsus Pharmaceuticals,

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Realaus laiko atnaujinimai Tarsus Pharmaceuticals, [TARS]

Upcoming Earnings Alert